Topline Results From ZEPHYR Trial ML-007C-MA for the Treatment of Schizophrenia
1 news trends Newsylist has tracked involving Topline Results From ZEPHYR Trial ML-007C-MA for the Treatment of Schizophrenia — newest first.
▲ Peaking
Business
🔮 holds
MapLight Therapeutics shares declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.
7 sources
7 articles
v 5
just now